Most recurrent somatic mutations recently evidenced in myeloid malignancies, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemias (AML), affect genes implicated in the regulation of gene expression (RUNX1, TEL/ETV6, TP53, TET2, ASXL1, EZH2, IDH1/2, DNMT3A). This evidence concerns the gene ASXL1 and myeloproliferative disorder.